EDITORIALS


Acesso aberto Revisado por pares

0

Visualização

Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses

Rodrigo Machado-Vieira1,2, João Quevedo2,3,4,5, Lokesh Shahani2, Jair C. Soares1,2,4

DOI: 10.1590/1516-4446-2020-0024

Epub: 7 de Janeiro de 2021

Vol.43 Issue 5/2021:

1Experimental Therapeutics and Molecular Pathophysiology Program, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA
2Center of Excellence in Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth, Houston, TX, USA
3Translational Psychiatry Program, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth, Houston, TX, USA
4Neuroscience Graduate Program, The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA
5Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), Criciúma, SC, Brazil

Corresponding author

Rodrigo Machado-Vieira, The University of Texas Health Science Center at Houston (UTHealth), McGovern Medical School, Faillace Department of Psychiatry and Behavioral Sciences, 1941 East Road, Houston, TX 77054, USA. E-mail: Rodrigo.MachadoVieira@uth.tmc.edu


© 2026 All rights reserved